CLEVELAND, July 15, 2015 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified dClinical™ technologies and delivering related services for the clinical trials industry, today announced that Cassiopea S.p.A., the newly IPO'd former subsidiary of longtime partner Cosmo Pharmaceuticals SA has selected DATATRAK for a significant global study.
"Technology should support clinical research, not complicate it," said Laurence P. Birch, Chairman and CEO, DATATRAK. "As long time DATATRAK users, Cosmo Pharmaceuticals knows firsthand that we simplify clinical research. We look forward to supporting the vital research of Cassiopeia and delivering an exceptional customer experience," concluded Birch.
"Success in clinical research requires software that lets us focus on the trial. It must be easy to use, protect patients, and provide insight on demand. DATATRAK delivers technology that supports our work without adding complicated processes," said Louise Dube, Director of R&D of Cassiopea S.p.A.
DATATRAK is a worldwide technology and consulting company delivering digital clinical solutions and related services for the clinical trials industry. The company delivers a portfolio of software solutions through the unified dClinical™ platform, safely accelerating clinical research, from Concept to Cure®.
Join DATATRAK Thought Leaders:
Tweet: Cosmo Pharmaceuticals extends DATATRAK partnership for upcoming Cassiopea global trial http://ow.ly/PBVAw
About DATATRAK International, Inc.
DATATRAK International is a worldwide technology and services company delivering unified dClinical™ solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via DATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK ONE® software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Preclinical and Phase I - Phase IV drug and device studies in multiple languages throughout the world. DATATRAK is located in Chicago, Illinois; Cleveland, Ohio; Bryan, Texas; Cary (RTP), North Carolina; and Plymouth, Minnesota. For more information, visit http://www.datatrak.com.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on March 13, 2015 announcing its results for the full-year period ended December 31, 2014. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
Cassiopea is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Initial focus is on the topical treatment of acne, androgenic alopecia (or AGA) and genital warts. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. For further information on Cassiopea, please visit www.cassiopea.com.
SOURCE DATATRAK International, Inc.